Allogeneic hematopoietic transplantation (allo-HCT) is one of the most advanced cell-based therapies available in the fight against complex conditions that can damage or disrupt bone marrow or immune system function.
The procedure, which involves a transplant of blood-forming stem cells from a donor with genetic similarities, provides patients a chance for remission in the fight against conditions like multiple myeloma, non-Hodgkin lymphoma and several types of acute and chronic leukemias, to name a few.
The procedure also remains one of the most effective treatments for most patients with acute myeloid leukemia (AML).
But what conditions should physicians see in their patients before employing allo-HCT?
New research from the Masonic Cancer Center, University of Minnesota, and the University of Minnesota Center for Immunology has identified key proteins that influence immune response strategies, a finding that could influence new vaccination approaches.
The study, published in the latest edition of Nature Immunology, looked closely at the KLF2 and S1P1 genes, and how their expression impacted the immune strategy of a cell.
The FDA has just given approval to a biotech drug from Roche to be used as a pre-surgical treatment for one of the deadliest forms of breast cancer.
The drug, known as Perjeta, has doctors hoping they can shrink tumors earlier, making them easier to remove. This would allow more women to keep their breasts instead of pursuing a full mastectomy, as well as increase positive outcomes for patients…
In a case of “what caused the cancer?” University of Minnesota scientists are aiming to find out if diet or environmental exposures to hazardous chemicals from a person’s past can be linked to a patient’s cancer today.
Health Talk recently sat down to discuss a noteworthy discovery made in the lab of researcher Robert Turesky, Ph.D., and postdoctoral fellow Byeong Hwa Yun, Ph.D., while the tandem were at the New York State Department of Health’s Wadsworth Center.